Can Assist Test – Breast

• Predict risk of recurrence in ER+, HER2- early stage (I/II) patients with Invasive ductal carcinoma (IDC) of breast and also aids in the Chemotherapy treatment decision.
• The test can stratify node negative (NO) and node-positive (NP) patients effectively across all ages, including early onset (<45 years) patients as well.
• This is the only test developed and validated on Indian patients.
• Results are binary (high risk or Low risk) with no intermediate risk zone, making it easier for physicians to make clinical decisions.
• The test has better prognostic ability when compared with Ki-67, PREDICT, IHC4 and showed good concordance with Oncotype Dx.

Eligibility criteria for CanAssist-Breast

• Patients with invasive ductal breast carcinoma
• Hormone receptor -positive (ER+, PR+/-)
• Her2neu receptor – negative (Her2-)
• Up to T3 tumor size
• Up to N1 (3 lymphnode positive)

Exclusion criteria for CanAssist-Breast

• ER- patients
• HER2+ patients
• Triple negative (TNBC) patients
• Patients treated with neo-adjuvant chemotherapy/hormone therapy